Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6138MR)

This product GTTS-WQ6138MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6138MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15628MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ10753MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ288MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ4256MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ2022MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ10083MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ15518MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ6464MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW